CIPO Patents = 3

EPO Patents = 4

Forward Citations = 109

Loading Chart...

7 inventors (with patents filed for the assignee):

Xiao Ke (2 out of 5 patents)

Xiaoping Gao (2 out of 2 patents)

Zunhong Ke (2 out of 2 patents)

4. Jianmin Fang (1 out of 59 patents)

5. Michael Dechao Yu (1 out of 1 patent)

6. Dechao Yu (1 out of 1 patent)

7. Zheng Liu (1 out of 4 patents)

8. Zheng Liu (0 patent)

6 patents: Sort by Forward Citations

1. 11944663 - Method for treating angiogenic eye disorders using VEGF antagonists (2024-04-02),

2. 9657084 - Fusion protein inhibiting angiogenesis or growth and use thereof (2017-05-23),

3. 9096669 - Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same (2015-08-04),

4. 8216575 - Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains (2012-07-10),

5. 7951585 - Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof (2011-05-31),

6. 7750138 - Angiogenesis-inhibiting chimeric protein and the use (2010-07-06),

Chengdu Kanghong Biotechnologies Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development and commercialization of innovative ophthalmic drugs. With a focus on treating eye diseases, Kanghong Biotechnologies has a strong pipeline of products and is committed to improving the quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

6 Patents

#34 in

#3,927 in China

CN

Chengdu Kanghong Biotechnologies Co., Ltd.

Forward Citations = 109

7 inventors:

Xiao Ke (2 out of 5 patents)

Xiaoping Gao (2 out of 2 patents)

Zunhong Ke (2 out of 2 patents)

4. Jianmin Fang (1 out of 59 patents)

5. Michael Dechao Yu (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com

3 patents (CIPO):

Please report any incorrect information to support@idiyas.com

4 patents (EPO):

Please report any incorrect information to support@idiyas.com